UROTHELIAL CARCINOMA

This study is testing a targeted drug called erdafitinib, both alone and combined with other treatments, for people with advanced bladder cancer that has spread or cannot be removed by surgery. The main goals are to find safe doses and see if these treatments can shrink tumors in…

This early-stage trial is testing a new drug called INBRX-106, both by itself and combined with an existing immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how …

This study is testing if adding a drug called durvalumab (an immunotherapy) to standard chemotherapy works better than chemotherapy alone for bladder cancer that has spread to nearby lymph nodes. The goal is to shrink the cancer more effectively before surgery. Patients will be r…

This early-stage study is testing whether combining two drugs—avelumab and AVB-S6-500—is safe for people with advanced bladder cancer that has spread or can't be surgically removed. The trial involves 19 participants who have already tried standard platinum-based chemotherapy. Re…

This study is testing whether giving two approved bladder cancer drugs less frequently can still control the disease while potentially reducing side effects. It involves 60 adults with advanced bladder cancer that has spread or cannot be surgically removed. The main goal is to se…

This early-stage trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy works better for treating advanced small cell or neuroendocrine cancers of the bladder, urethra, or prostate. The study will enroll about 15 participants with cancer tha…

This study is testing a new combination of immune-boosting drugs for people with advanced cancers whose disease has progressed after treatment with standard immunotherapies like pembrolizumab or nivolumab. It aims to see if adding a drug called NAI to other treatments can help sh…

This study is testing whether adding a newer immunotherapy drug (atezolizumab) to standard chemotherapy (gemcitabine and cisplatin) is safe and effective for bladder cancer. It involves two groups of patients: those with cancer that has spread (metastatic) and those with cancer t…

This study is testing an investigational drug called TYRA300 for people with advanced bladder cancer and other solid tumors that have specific changes in a gene called FGFR3. The main goals are to find a safe and effective dose and to see if the drug can shrink or control the tum…

This was an early safety study for people with advanced bladder cancer that had spread. It aimed to test a combination of three drugs to see if they could control the cancer and were safe to use together. The study was withdrawn before any participants were enrolled.

This early-stage study is testing the safety and feasibility of new ways to deliver an immune-boosting drug called IMP321 to people with advanced solid tumors. Researchers are trying methods like injecting the drug directly into tumors or into the abdominal cavity, and combining …

This study is testing new drug combinations for people with advanced bladder cancer that has stopped responding to standard immunotherapy. It will enroll 48 participants whose cancer has progressed despite previous treatment. The trial aims to find new options to control the dise…

This large, late-stage study is comparing a new two-drug combination (disitamab vedotin plus pembrolizumab) against standard chemotherapy for people with advanced bladder cancer that has spread. The goal is to see if the new combination works better to control the cancer and help…

This study is testing a new liquid treatment called UGN-103 for people with a specific type of early-stage bladder cancer that has a moderate risk of returning. The treatment is placed directly into the bladder once a week for six weeks. Researchers want to see if it can complete…

This is an early-stage study to see if a new type of cell therapy is safe and feasible for people with a specific type of bladder cancer that has come back after standard treatment. The therapy involves collecting a patient's own immune cells from their tumor, growing more of the…

This study is testing a new treatment called cretostimogene to see if it can prevent intermediate-risk bladder cancer from returning after tumor removal surgery. About 367 participants will be randomly assigned to receive either the new treatment or standard observation with regu…

This study aimed to see if a targeted pill (erdafitinib) alone or combined with an immunotherapy drug (atezolizumab) could shrink aggressive bladder tumors before surgery. It was for patients whose cancer had grown into the muscle wall of the bladder and who could not receive the…

This early-to-mid stage trial is testing whether a new two-drug combination can help control advanced bladder, kidney, or skin cancers. The study is for people whose cancer has spread or returned after trying at least one other treatment. Researchers want to see if the drugs, whi…

This early-stage trial is testing a new antibody drug called acasunlimab (GEN1046) for people with advanced solid tumors. The study first aims to find safe doses, then tests how well those doses work when given alone or combined with other cancer drugs. All 429 participants will …

This early safety study aims to find the right dose and understand the side effects of a new drug combination for people with advanced solid tumors who also have liver or kidney problems. It tests adding a pill called veliparib to standard chemotherapy drugs. The main goal is to …

This study is testing a combination of three drugs for people with advanced bladder cancer that has a specific genetic flaw called MTAP deficiency and has stopped responding to standard immunotherapy. The goal is to see if this new combination is safe and can help control the can…

This study aims to find out if a newer, faster type of CT scan is just as good at finding cancers in the urinary tract (like bladder cancer) as the standard, longer scan. It will enroll 352 patients who are over 40, have symptoms like blood in their urine, or have a history of th…

This study is testing a new type of PET scan to see if it can more accurately determine how far muscle-invasive bladder cancer has spread compared to standard CT or MRI scans. Researchers will enroll 16 participants who are scheduled for bladder removal surgery. The goal is to se…

This study aims to find new chemical markers in the blood and urine that could help detect kidney and bladder cancers. Researchers are collecting samples from 589 people, including those with these cancers and healthy individuals, to compare and identify reliable markers. The goa…

This study looks back at medical records of 360 Japanese patients with advanced bladder cancer who received avelumab maintenance therapy after initial chemotherapy. Researchers want to understand patient characteristics, treatment patterns, and survival outcomes. The study doesn'…

This early-stage study is testing a new imaging agent called 68Ga-FAPI-46 to see where it goes in the body of patients with many different types of cancer. The goal is to understand if this tracer can help doctors better see and understand tumors by highlighting specific cells ar…

This study is observing how well the immunotherapy drug atezolizumab works and its safety for patients with advanced lung, bladder, or liver cancer in real-world medical settings. It involves over 2,700 patients who are already receiving this drug as part of their standard care. …